Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Raw Materials (2018 - 2025)

Historic Raw Materials for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $20.3 million.

  • TransMedics' Raw Materials fell 2777.48% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year decrease of 2777.48%. This contributed to the annual value of $28.0 million for FY2024, which is 853.5% up from last year.
  • As of Q3 2025, TransMedics' Raw Materials stood at $20.3 million, which was down 2777.48% from $19.2 million recorded in Q2 2025.
  • In the past 5 years, TransMedics' Raw Materials ranged from a high of $28.0 million in Q3 2024 and a low of $6.1 million during Q1 2021
  • Its 5-year average for Raw Materials is $16.3 million, with a median of $15.1 million in 2023.
  • In the last 5 years, TransMedics' Raw Materials soared by 13606.36% in 2023 and then crashed by 3035.34% in 2025.
  • TransMedics' Raw Materials (Quarter) stood at $7.3 million in 2021, then skyrocketed by 50.38% to $10.9 million in 2022, then skyrocketed by 136.06% to $25.8 million in 2023, then rose by 8.54% to $28.0 million in 2024, then fell by 27.72% to $20.3 million in 2025.
  • Its Raw Materials was $20.3 million in Q3 2025, compared to $19.2 million in Q2 2025 and $24.9 million in Q1 2025.